<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01513694</url>
  </required_header>
  <id_info>
    <org_study_id>CSM/Fusión/2009</org_study_id>
    <nct_id>NCT01513694</nct_id>
  </id_info>
  <brief_title>Clinical Trial Based on the Use of Mesenchymal Stem Cells From Autologous Bone Marrow in Patients With Lumbar Intervertebral Degenerative Disc Disease</brief_title>
  <official_title>Clinical Trial Phase I / II Prospective, Open, Non-randomized for Treatment of Lumbar Intervertebral Degenerative Disc Disease With Posterolateral Instrumented and Autologous Mesenchymal Stem Cells.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Red de Terapia Celular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Haematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo Fernández-Roldán</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spanish National Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Red de Terapia Celular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to test the effectiveness of the use of a new therapeutic
      strategy in treating patients with degenerative disc disease lumbar intervertebral fusion
      with instrumented posterolateral autologous mesenchymal stem cells and arranged in a calcium
      phosphate ceramic (Conduit TM).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">May 4, 2017</completion_date>
  <primary_completion_date type="Actual">May 4, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Intervertebral Disc Disease</condition>
  <arm_group>
    <arm_group_label>MSC seeded onto a phosphate ceramic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Instrumented posterolateral fusion and autologous mesenchymal stem cells arranged in a phosphate ceramic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Instrumented posterolateral arthrodesis</intervention_name>
    <description>Cell suspension of mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.
They used a minimum dose of 0.5 x106 CSM / kg and a maximum of 1, 5x106 CSM / kg of patient weight.
Dosage Form: Suspension cell support hydroxyapatite and calcium phosphate Route of administration: placement in the fusion bed during surgery.</description>
    <arm_group_label>MSC seeded onto a phosphate ceramic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Clinical

          -  Box symptomatic (back pain and / or root) of lumbar degenerative disc disease
             monosegmental.

          -  Discopathy refractory to conservative treatment (drugs, physical therapy.)

          -  Evolution greater than or equal to 6 months. Radiological

          -  Discopathy radiation. Disc space narrowing, osteophytes, abnormal mobility, etc

          -  NMR: grades IV and V of Pfirman.

        Exclusion Criteria:

          -  Rejection of surgical treatment.

          -  Systemic inflammatory disease (spondylitis, rheumatoid arthritis etc), tumor or
             infection.

          -  Immunosuppressive treatment.

          -  Congenital or acquired anatomical abnormality that prevents the surgical procedure.

          -  Neuropsychiatric pathology, drug addiction, psychosis, severe personality disorder.

          -  High surgical risk (ASA&gt; IV), or contraindication to anesthesia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Trauma Service. Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla-León</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.red-tercel.com</url>
    <description>Spanish cell therapy network (TerCel)</description>
  </link>
  <link>
    <url>http://fundacion.usal.es</url>
    <description>Salamanca University Foundation</description>
  </link>
  <link>
    <url>http://www.isciii.es</url>
    <description>Spanish Health Institute Carlos III</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2012</study_first_submitted>
  <study_first_submitted_qc>January 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2012</study_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mesenchymal Stem Cells</keyword>
  <keyword>Stem Cells</keyword>
  <keyword>Intervertebral disc disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Diseases</mesh_term>
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
    <mesh_term>Intervertebral Disc Displacement</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

